CD8A and head and neck cancer: Recent studies across various solid tumors including colorectal, lung, esophageal, and head and neck cancers have demonstrated that the presence of Ttex, particularly when quantified relative to total CD8+ T cells (Ttex/CD8+ ratio), can serve as a prognostic indicator of patient outcomes (8, 9).